Skip to main content
. 2021 Jun 29;10(13):2905. doi: 10.3390/jcm10132905

Figure 3.

Figure 3

Effect of a 15-month TNFαI therapy on markers of osteoclastogenesis: sRANKL (a) and OPG (b) in women with rheumatoid arthritis, and in healthy women. a** p < 0.001 compared to the control, b** p < 0.001 compared to the baseline. OPG, osteoprotegerin; RA, rheumatoid arthritis; sRANKL, total soluble receptor activator of nuclear factor κB ligand; TNFαI, tumor necrosis factor α inhibitors.